NEXGEL (NXGL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Jun, 2026Executive summary
The annual meeting will address seven proposals, including director elections, approval of significant share issuances, reincorporation to Nevada, increases in authorized shares, a reverse stock split, executive compensation, and auditor ratification.
The Board recommends voting in favor of all proposals, emphasizing the importance of shareholder participation.
The meeting is scheduled for July 10, 2026, with proxy materials available online and by mail.
Voting matters and shareholder proposals
Seven proposals include: election of seven directors, approval of share issuance exceeding 19.99% for private placements, reincorporation to Nevada, increase in authorized shares, discretionary reverse stock split, advisory vote on executive compensation, and auditor ratification.
Proposals 4 and 5 serve as Delaware-law fallbacks if reincorporation (Proposal 3) is not approved.
Approval thresholds vary: most require a majority of outstanding shares, while director elections require a plurality.
Shareholders may vote by internet, phone, or mail, and can revoke proxies before the meeting.
Board of directors and corporate governance
Seven directors are nominated, with detailed biographies provided for each.
Five directors are independent per Nasdaq standards; the CEO and one director are not independent due to related party transactions.
The Board has Audit, Compensation, and Nominating & Corporate Governance Committees, all with independent members.
The Board held seven meetings in 2025, with all directors attending at least 75% of meetings.
The company has a Code of Business Conduct and Ethics, insider trading and hedging policies, and a compensation recovery policy.
Latest events from NEXGEL
- Vote sought on share increase, reverse split, and adjournment to support capital flexibility and Nasdaq compliance.NXGL
Proxy filing - Surgeon-focused platform leverages strategic assets and partnerships to drive innovation and growth.NXGL
Investor presentation - Expanded regenerative medicine portfolio and direct sales force set stage for rapid growth.NXGL
Planet MicroCap Las Vegas 2026 - Annual meeting seeks approval for director elections, stock issuance, reincorporation, and capital changes.NXGL
Proxy filing - Major acquisition expected to triple annual revenue and improve profitability.NXGL
Q1 2026 - Revenue up 31.5% to $11.4M, but net loss of $3.0M and going concern risks persist.NXGL
Q4 2025 - Acquisition and partnership triple revenue, drive profitability, and expand into regenerative medicine.NXGL
M&A announcement - Record Q2 revenue of $1.44M, with strong outlook driven by branded and Silly George growth.NXGL
Q2 2024 - Q1 2025 revenue up 121% to $2.81M, gross margin at 42.4%, and net loss narrowed.NXGL
Q1 2025